In recent years, the state is constantly introducing various policies to promote the high-quality development of the children's drug industry, and at the same time, the children's drug market has also ushered in rare opportunities
for development.
For example, since 2008, the Health Commission has invested 600 million yuan through the special project of new drugs to support the research and development of children's drugs and clinical research; The National Children's Medical Center was established, and 23 pediatric medical institutions were united to establish the "China Pediatric Population Drug Clinical Trial Collaboration Network" to promote pediatric clinical trials
.
In the whole year of 2021, a total of 47 children's special drugs and drugs with increased children's application were approved for marketing, and 14 were included in the priority review and approval sequence, and the number of declarations and approvals for children's drugs is showing a steady upward trend
.
At present, under the favorable policies and the continuous expansion of the market, more and more pharmaceutical companies have also begun to continue to increase the research and development
of children's drugs.
For example, Kangzhi Pharmaceutical has been deeply engaged in the field of children's medicine for many years, and has three major technical platforms
: "Oral Instant Film Agent", "Preparation of Ultra-fine Particles of Drugs" and "Microscopic Morphological Structure Detection of Pharmaceutical Powder".
Recently, it disclosed a fundraising plan, which intends to raise no more than 297 million yuan through a private placement for children's drug research and development projects to improve the company's research and development conditions and enhance research and development strength
.
It is worth noting that the research and development project of Kangzhi Pharmaceutical includes the research and development of drugs in a total of 5 categories from the code Honz-030 to Honz-034, mainly for children's colds, fevers, coughs, pneumonia and allergic diseases
.
On July 30, Sunflower Pharmaceutical also issued an announcement that the company intends to invest 54 million yuan to invest in the establishment of a wholly-owned subsidiary, Beijing Sunflower Pharmaceutical Research Co.
, Ltd.
, to build a technology research and development platform focusing on children's preparations, so as to further strengthen the company's main business of children's medicines, and strengthen the research and development of children's drugs, and actively respond to policy orientation
.
The company said that it will make full use of the location advantage of the proposed company to absorb and introduce talents in the field of children's preparations at home and abroad, and is committed to the introduction of children's preparation technology at home and abroad, the research and development of children's imitation preparations, and the upgrading
of the company's existing varieties and technologies in the field of children's medication.
In addition to the above enterprises, a number of new Biotechs, including Tianjing Biologics, AGCO Baifa, Weisheng Pharmaceutical, Baitai Biologics, Beimei Pharmaceutical, etc.
, are also entering the children's medicine track
in various forms such as cooperation.
The industry expects that as children's drugs receive more and more attention from all parties, and relevant policies continue to support the research and development of children's drugs, the level of children's drugs in China will be significantly improved
in the future.
In fact, in recent years, under the strong promotion of national policies, the level of children's medication in China has been significantly improved
.
The data shows that in 2021, a total of 47 children's drugs were approved for marketing, which significantly improved the level of clinical drugs, of which 14 were included in the priority review and approval, which greatly promoted the listing process
of children's drugs.
There are more children's drugs in the application process, as these drugs have been approved for listing, the industry is expected that in the future, while benefiting more patients, it will further promote the development of China's children's drug industry
.
